Augustine Therapeutics will present preclinical efficacy data for an HDAC6 inhibitor in heart failure with preserved ejection fraction at the American Diabetes Association conference in June 2026. This work addresses a mechanistic intersection between metabolic dysfunction and cardiac dysfunction, relevant to age-related disease prevention.
Key Points
- HDAC6 inhibitor shows efficacy in HFpEF mouse models
- Non-hydroxamate chemotype designed for chronic disease safety
- EUR 78 million Series A funding supports development pipeline
Longevity Analysis
Heart failure with preserved ejection fraction represents a growing clinical challenge in aging populations, often linked to metabolic derangement and inflammatory pathways. HDAC6 inhibition addresses protein homeostasis and stress response regulation at the cellular level, mechanisms that degrade across the lifespan. The focus on a selective, non-hydroxamate approach signals recognition that broad HDAC inhibition carries tolerability constraints in chronic dosing—a prerequisite for sustained intervention in age-related disease. This represents progress in identifying tractable targets at the intersection of metabolic and cardiac function.
Original published by LT Wire.